Clopidogrel und Protonenpumpeninhibitoren – Fluch
oder Segen?

J Labenz; W Meyners; K-U Petersen

doi:10.1055/s-0029-1244837

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2010; 135(5): 203-206
DOI: 10.1055/s-0029-1244837

Kommentar | Commentary

Gastroenterologie, Pharmakologie
© Georg Thieme Verlag KG Stuttgart · New York

Clopidogrel und Protonenpumpeninhibitoren – Fluch oder Segen?

Clopidogrel and proton pump inhibitors – boon or bane?J. Labenz¹ ^, ² , W. Meyners¹ , K-U. Petersen³

¹Medizinische Klinik mit Gastroenterologie und Kardiologie Ev. Jung-Stilling-Krankenhaus Siegen
²Medizinische Fakultät der Universität Duisburg-Essen
³ Medizinische Fakultät der RWTH Aachen

Abstract

Schlüsselwörter

Protonenpumpenhemmer - Clopidogrel - Interaktion - Cytochrom P450 2C19

Keywords

protone pump inhibitors - Clopidogrel - drug interaction - Cytochrome P450 2C19

Full Text

References

Literatur

1 Adamopoulos A B, Sakizlis G N, Nasothimiou E G. et al . Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomised crossover study. J Cardiovasc Pharmacol. 2009; 54 163-168
2 Bonzel T, Erbel R, Hamm C W. et al . Perkutane Koronarinterventionen (PCI). Clin Res Cardiol. 2008; 97 513-547
3 CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996; 348 1329-1339
4 Cuisset T, Frere C, Quilici J. et al . Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009; 54 1149-1153
5 Fischbach W, Malfertheiner P, Hoffmann J C. et al . S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol. 2009; 47 68-102
6 Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Brit Med J. 2008; 336 2-3
7 Gilard M, Arnaud B, Cornily J C. et al . Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008; 51 256-260
8 Grines C L, Bonow R O, Casey Jr D E . et al . Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation. 2007; 115 813-818
9 Heidelbaugh J J, Goldberg K O, Inadomi J M. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk in PPI. Am J Gastroenterol. 2009; 104 S27-S32
10 Ho P M, Maddox T M, Wang L. et al . Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301 937-944
11 Juurlink D N, Gomes T, Ko D T. et al . A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180 713-718
12 Lahner E, Annibale B, Delle Fave G. Systemic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009; 29 1219-1229
13 Li X Q, Andersson T B, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabol Dispos. 2004; 32 821-827
14 Mega J L, Close S AL, Wiviott S D. et al . Cytochrome P-450 polymorphisms and response to Clopidogrel. N Engl J Med. 2009; 360 354-362
15 Ng F H, Lam K F, Chang C M. et al . Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion. 2008; 77 173-177
16 O’Donoghue M L, Braunwald E, Antman E M. et al . Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009; 374 989-997
17 Petersen K U. Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel. Arzneimittelforschung. 2009; 59 213-227
18 Rosemary J, Adithan C. The pharmacogenetics of CYP 2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol. 2007; 2 93-109
19 Sibbing D, Morath T, Stegherr J. et al . Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009; 101 714-719
20 Silber S, Borggrefe M, Böhm M. et al . Medikamente freisetzende Koronarstents (DES) und Medikamente freisetzende Ballonkatheter (DEB): Aktualisierung des Positionspapiers der DGK. Clin Res Cardiol. 2008; 97 548-563
21 Siller-Matula J M, Spiel A O, Lang I M. et al . Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157,148 e1-5
22 Simon T, Verstuyft C, Mary-Krause M. et al . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360 363-375
23 Taha A S, McCloskey C, Prasad R, Bezylak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374 119-125
24 Wallentin N, Becker R C, Budaj A. et al . Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361 1045-1057

Prof. Dr. med. Joachim Labenz

Medizinische Klinik, Ev. Jung-Stilling-Krankenhaus, Akademisches Lehrkrankenhaus der Universität Bonn

Wichernstr. 40

57074 Siegen

Email: Joachim.Labenz@diakonie-sw.de